
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 14, 2008

Date of Report

(Date of earliest event reported)

A.P. PHARMA, INC.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

000-33221
(Commission File Number)

94-2875566
(I.R.S. Employer
Identification No.)

123 Saginaw Drive
Redwood City, California 94063

(Address of principal executive offices) (Zip code)

(650) 366-2626

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 14, 2008, A.P. Pharma, Inc., a Delaware corporation (the "Company"), issued a press release, attached hereto as Exhibit 99.1 to this Form 8-K, announcing that Michael O'Connell, Chief Financial Officer of the Company, is leaving the Company on January 18, 2008. Mr. O'Connell will continue to act as the Company's principal financial officer and principal accounting officer until his departure. Following that, Gregory Turnbull, President and Chief Executive Officer of the Company, will serve as principal financial officer and principal accounting officer on an interim basis until a successor is appointed. The Company will commence a search for a new Chief Financial Officer.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release of A.P. Pharma, Inc. dated January 14, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

A.P. PHARMA, INC.

Date: January 15, 2008

By: /s/ Gregory Turnbull

Name: Gregory Turnbull

Title: President and Chief Executive Officer



News Release

A.P. PHARMA ANNOUNCES EXECUTIVE OFFICER DEPARTURE

REDWOOD CITY, Calif. (January 14, 2008) – A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, announced today that Michael O’Connell, its Chief Operating Officer and Chief Financial Officer, will be leaving the company on January 18, 2008. Mr. O’Connell originally joined A.P. Pharma in 1992 as Vice President and Chief Financial Officer. In 2000 he was named President and Chief Executive Officer, and served in that capacity until departing in October of 2006 on medical leave. He rejoined the management team in mid-2007 in his present capacity. Upon his resignation, Mr. O’Connell will be entitled to the benefits of a retention agreement that are payable due to his not being reappointed to the position of President and Chief Executive Officer.

The company will be conducting a search for a new Chief Financial Officer. Until a successor is engaged Gregory Turnbull, the company’s current President and Chief Executive Officer, will also handle the duties of the Chief Financial Officer on an interim basis.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company’s primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer™. Initial target areas of application for the Company’s drug delivery technology include anti-nausea, pain management, anti-inflammation and DNA/RNAi applications. For further information visit the Company’s web site at www.appharma.com.

Investor Relations Contacts:

Lippert/Heilshorn & Associates
Don Markley (dmarkley@lhai.com)
(310) 691-7100

Company Contact:

Gregory Turnbull
President and Chief Executive Officer
(650) 366-2626
